Chinese Journal of Clinical Hepatology最新文献

英文中文

IDDF2022-ABS-0170 Hypoxia and R-factor: predictors of abnormal lft in covid-19 低氧和r因子:covid-19患者异常左移的预测因素

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.109

W. Chew, Jonathan Kuang, Huiyu Lin, L. Ang, W. Yang, D. Lye, B. Young

IDDF2022-ABS-0170 Table 1Demographics, comorbidities, laboratory investigations and clinical outcomes of COVID-19 patients stratified by ALT All (n=163) Status of ALT P-value¶ Characteristics Abnormal (n=50) Normal (n=113) Age in years, median (IQR) 56 (43–65) 60 (50–67) 55 (37–64) 0.022 Gender, n (%) 0.124 Male 96 (58.9) 34 (68.0) 62 (54.9) Female 67 (41.1) 16 (32.0) 51 (45.1) Ethnic group, n (%) 0.520 Chinese 98 (60.1) 34 (68.0) 64 (56.6) Malay 18 (11.0) 4 (8.0) 14 (12.4) Indian 20 (12.3) 6 (12.0) 14 (12.4) Others 27 (16.6) 6 (12.0) 21 (18.6) Comorbidities, n (%) Diabetes 32 (19.6) 13 (26.0) 19 (16.8) 0.201 Hyperlipidemia 57 (35.0) 24 (48.0) 33 (29.2) 0.032 Hypertension 61 (37.4) 26 (52.0) 35 (31.0) 0.014 Ischemic heart disease 15 (9.2) 7 (14.0) 8 (7.1) 0.238 Chronic liver disease 4 (2.5) 1 (2.0) 3 (2.7) 1.000 Charlson Comorbidity Index, median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0.400 BMI, kg/m2, median (IQR), n=46 24.3 (23.2–27.9) 22.9 (22.1–24.2) 24.6 (23.6–28.7) 0.011 GI symptoms, n (%) Diarrhoea 29 (17.8) 12 (24.0) 17 (15.0) 0.186 Abdominal pain 4 (2.5) 0 (0.0) 4 (3.5) 0.313 Nausea/vomiting 10 (6.1) 0 (0.0) 10 (8.8) 0.032 Abnormal chest radiography on admission 55 (33.7) 22 (44.0) 33 (29.2) 0.074 Laboratory investigations on admission, median (IQR) ALT, U/L 23 (18–31) 29 (22–33) 21 (17–26) <0.0005 ALT/LDH ratio, n=162 0.05 (0.04–0.07) 0.06 (0.04–0.07) 0.05 (0.03–0.06) 0.039 ALP 72 (60–89) 72 (61–90) 72 (60–89) 0.700 R factor 0.94 (0.70–1.26) 1.15 (0.86–1.49) 0.87 (0.63–1.19) <0.0005 WBC, x109/L 4.70 (3.80–5.70) 4.75 (3.80–5.83) 4.70 (3.85–5.70) 0.844 Lymphocyte, x109/L 1.11 (0.84–1.49) 0.99 (0.74–1.23) 1.20 (0.87–1.65) 0.002 PLT, x 109/L 188 (150–225) 177 (142–223) 193 (155–226) 0.306 CRP, mg/L, n=162 10.75 (3.15–39.40) 30.10 (11.28–50.65) 6.85 (1.95–23.88) <0.0005 LDH, U/L, n=162 420 (350–547) 482 (378–572) 408 (342–525) 0.033 Creatinine, μmol/L 72 (61–87) 76 (65–88) 71 (59–87) 0.288 Albumin, g/L, n=156 39 (37–42) 39 (37–41) 40 (37–43) 0.044 BIL, μmol/L, n=152 11 (9–14) 11 (9–14) 12 (9–15) 0.555 Medication used, n (%) NSAIDs 22 (13.5) 4 (8.0) 18 (15.9) 0.218 β-lactam 47 (28.8) 22 (44.0) 25 (22.1) 0.008 Hydroxychloroquine 7 (4.3) 1 (2.0) 6 (5.3) 0.677 Lopinavir/Ritonavir (Kaletra) 25 (15.3) 16 (32.0) 9 (8.0) <0.0005 Remdesivir 12 (7.4) 5 (10.0) 7 (6.2) 0.516 Interferon 9 (5.5) 6(12.0) 3 (2.7) 0.025 Days of symptoms before admission, median (IQR) 4 (3–7) 4 (2–7) 5 (3–7) 0.396 Length of stay in days, median (range) 13(8–17) 16(13–24) 11 (7–16) <0.0005 Clinical severity HDU/ICU, n (%) 29 (17.8) 16 (32.0) 13 (11.5) 0.003 Required supplementary oxygen, n (%) 50 (30.7) 29 (58.0) 21 (18.6) <0.0005 Days on supplementary oxygen, median (IQR), n=50 11 (6–18) 12 (6–21) 8 (5–15) 0.15 Intubated, n (%) 13 (8.0) 10 (20.0) 3 (2.7) <0.0005 Death, n (%) 5 (3.1) 3 (6.0) 2 (1.8) 0.169 Sample size, n=163, except where indicated.¶ P values are from Fisher’s exact test or chi-square test for categorical variables and Mann-Whitney U test for continuous variables. P val

00参照物1.00参照物≥1 3.12(1.56-6.24)0.001 3.13(1.41-6.95)0.005对乙酰氨基酚使用No 1.00参照物Yes， <2 g/天1.48 (0.39-5.65)0.567 Yes，≥2 g/d 2.86 (0.71-11.46) 0.139 β-内酰胺使用2.77(1.35-5.65)0.005 1.12(0.38-3.24)0.840羟氯喹使用0.36(0.04-3.11)0.355洛匹那韦/利托那韦(Kaletra)使用5.44(2.20 - 13.43)<0.0005 2.20(0.57-8.45)0.252瑞德西韦使用1.68(0.51-5.58)0.395干扰素使用5.00(1.20-20.88)0.027 0.80(0.12-5.22)0.813缺氧6.05(2.9-12.62)<0.0005 3.54(1.29-9.69)0.014‡多变量logistic回归模型的变量为年龄、高血脂、高血压、入院时胸片异常、入院时R因子、β-内酰胺使用情况、LPV/ R使用情况、干扰素使用情况、缺氧情况，黑体、aOR、校正优势比、cOR、粗优势比IDDF2022-ABS-0170 P值均<0.05。图1结论银损伤与COVID-19患者临床预后较差相关。入院时r因子≥1和缺氧是COVID-19发生ALT异常的独立危险因素。将r因子纳入常规临床风险评分是否可以提高预测疾病进展/区分疾病严重程度的性能，以及在新出现的病毒变体中的适用性，还需要更多的研究。

{"title":"IDDF2022-ABS-0170 Hypoxia and R-factor: predictors of abnormal lft in covid-19","authors":"W. Chew, Jonathan Kuang, Huiyu Lin, L. Ang, W. Yang, D. Lye, B. Young","doi":"10.1136/gutjnl-2022-iddf.109","DOIUrl":"https://doi.org/10.1136/gutjnl-2022-iddf.109","url":null,"abstract":"IDDF2022-ABS-0170 Table 1Demographics, comorbidities, laboratory investigations and clinical outcomes of COVID-19 patients stratified by ALT All (n=163) Status of ALT P-value¶ Characteristics Abnormal (n=50) Normal (n=113) Age in years, median (IQR) 56 (43–65) 60 (50–67) 55 (37–64) 0.022 Gender, n (%) 0.124 Male 96 (58.9) 34 (68.0) 62 (54.9) Female 67 (41.1) 16 (32.0) 51 (45.1) Ethnic group, n (%) 0.520 Chinese 98 (60.1) 34 (68.0) 64 (56.6) Malay 18 (11.0) 4 (8.0) 14 (12.4) Indian 20 (12.3) 6 (12.0) 14 (12.4) Others 27 (16.6) 6 (12.0) 21 (18.6) Comorbidities, n (%) Diabetes 32 (19.6) 13 (26.0) 19 (16.8) 0.201 Hyperlipidemia 57 (35.0) 24 (48.0) 33 (29.2) 0.032 Hypertension 61 (37.4) 26 (52.0) 35 (31.0) 0.014 Ischemic heart disease 15 (9.2) 7 (14.0) 8 (7.1) 0.238 Chronic liver disease 4 (2.5) 1 (2.0) 3 (2.7) 1.000 Charlson Comorbidity Index, median (IQR) 0 (0–1) 0 (0–1) 0 (0–1) 0.400 BMI, kg/m2, median (IQR), n=46 24.3 (23.2–27.9) 22.9 (22.1–24.2) 24.6 (23.6–28.7) 0.011 GI symptoms, n (%) Diarrhoea 29 (17.8) 12 (24.0) 17 (15.0) 0.186 Abdominal pain 4 (2.5) 0 (0.0) 4 (3.5) 0.313 Nausea/vomiting 10 (6.1) 0 (0.0) 10 (8.8) 0.032 Abnormal chest radiography on admission 55 (33.7) 22 (44.0) 33 (29.2) 0.074 Laboratory investigations on admission, median (IQR) ALT, U/L 23 (18–31) 29 (22–33) 21 (17–26) <0.0005 ALT/LDH ratio, n=162 0.05 (0.04–0.07) 0.06 (0.04–0.07) 0.05 (0.03–0.06) 0.039 ALP 72 (60–89) 72 (61–90) 72 (60–89) 0.700 R factor 0.94 (0.70–1.26) 1.15 (0.86–1.49) 0.87 (0.63–1.19) <0.0005 WBC, x109/L 4.70 (3.80–5.70) 4.75 (3.80–5.83) 4.70 (3.85–5.70) 0.844 Lymphocyte, x109/L 1.11 (0.84–1.49) 0.99 (0.74–1.23) 1.20 (0.87–1.65) 0.002 PLT, x 109/L 188 (150–225) 177 (142–223) 193 (155–226) 0.306 CRP, mg/L, n=162 10.75 (3.15–39.40) 30.10 (11.28–50.65) 6.85 (1.95–23.88) <0.0005 LDH, U/L, n=162 420 (350–547) 482 (378–572) 408 (342–525) 0.033 Creatinine, μmol/L 72 (61–87) 76 (65–88) 71 (59–87) 0.288 Albumin, g/L, n=156 39 (37–42) 39 (37–41) 40 (37–43) 0.044 BIL, μmol/L, n=152 11 (9–14) 11 (9–14) 12 (9–15) 0.555 Medication used, n (%) NSAIDs 22 (13.5) 4 (8.0) 18 (15.9) 0.218 β-lactam 47 (28.8) 22 (44.0) 25 (22.1) 0.008 Hydroxychloroquine 7 (4.3) 1 (2.0) 6 (5.3) 0.677 Lopinavir/Ritonavir (Kaletra) 25 (15.3) 16 (32.0) 9 (8.0) <0.0005 Remdesivir 12 (7.4) 5 (10.0) 7 (6.2) 0.516 Interferon 9 (5.5) 6(12.0) 3 (2.7) 0.025 Days of symptoms before admission, median (IQR) 4 (3–7) 4 (2–7) 5 (3–7) 0.396 Length of stay in days, median (range) 13(8–17) 16(13–24) 11 (7–16) <0.0005 Clinical severity HDU/ICU, n (%) 29 (17.8) 16 (32.0) 13 (11.5) 0.003 Required supplementary oxygen, n (%) 50 (30.7) 29 (58.0) 21 (18.6) <0.0005 Days on supplementary oxygen, median (IQR), n=50 11 (6–18) 12 (6–21) 8 (5–15) 0.15 Intubated, n (%) 13 (8.0) 10 (20.0) 3 (2.7) <0.0005 Death, n (%) 5 (3.1) 3 (6.0) 2 (1.8) 0.169 Sample size, n=163, except where indicated.¶ P values are from Fisher’s exact test or chi-square test for categorical variables and Mann-Whitney U test for continuous variables. P val","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75099142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IDDF2022-ABS-0046 Social life and financial barriers of thai HCC survivors: a cross-sectional survey 泰国HCC幸存者的社会生活和经济障碍:一项横断面调查

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.91

P. Wanchaijiraboon, Naiyarat Prakongsook, K. Pongpirul, C. Chumsri, P. Kantagowit, Phanupong Phutrakook, P. Tangkijvanich, W. Sukeepaisarnjareon

引用次数: 0

IDDF2022-ABS-0125 Comparative burden of metabolic dysfunction nafld in lean. A meta analysis 瘦人代谢功能障碍的比较负担。meta分析

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.100

C. Ng, K. Chan, A. Tang, P. Phang, M. Siddiqui, A. Sanyal, M. Muthiah, M. Noureddin

引用次数: 0

IDDF2022-ABS-0071 EUS guided coil and glue for gastric varices- one therapy to rule them all? EUS引导胃静脉曲张线圈和胶水-一种治疗方法可以治疗所有静脉曲张?

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.94

Z. Sharma, R. Puri, S. Bhagat, A. Kathuria

引用次数: 0

IDDF2022-ABS-0185 Tinospora cordifolia induced liver injury during covid-19 pandemic 新型冠状病毒大流行期间cordifolia Tinospora诱导的肝损伤

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.115

Sowmya Iyengar, A. Kulkarni, Mithun Sharma, D. Nageshwar Reddy, P. Rao

IDDF2022-ABS-0185 Table 1Clinical characteristics of patients with Giloy-induced liver injuryCharacteristics Number of patients (Total-16 patients) Gender Male 7 (43.75%) Female 9 (56.25%) Age (mean ± SD) 48.3±14 years Presentation type Acute hepatitis 6 (37.5%) ACLF 10 (62.5%) Mean duration for symptom onset after consumption of giloy 84.3±35 days Mean BMI 23.23±3 kg/m2 Comorbidities Type 2 diabetes 9 (56.25%) Interstitial lung disease (on inhalational steroids) 2 (12.5%) Hypertension 1 (6.25%) None 5 (31.25%) NAFLD 2 (6.25%) Symptoms Jaundice 16 (100%) Ascites 8 (50%) Fatigue 12 (75%) Pruritus 4 (25%) Liver function tests Peak total bilirubin (Mean ± SD) 17 ± 9.4 mg/dl Peak ALT (mean ± SD) 365± 219 U/L Peak AST (mean ± SD) 558 ± 475 U/L Peak ALP (mean ± SD) 186 ± 114 U/L Peak serum IgG (mean ± SD) 2400 ± 1213 mg/dl Peak INR (mean ± SD) 2.63 ± 1.05 AIH serology ANA 1(6.25%) ASMA - Anti LKM1 - AMA - Seronegative (biopsy proven) - Liver biopsy 10 (62.5) Drug induced liver injury 5 (31.25%) Features of AIH 5 (31.25%) Treatment N-Acetyl Cysteine infusion+Ademetionine 3 (18.75%) Steroids 10 (62.5%) Plasma Exchange 3 (18.75%) Outcome Alive 16 (100%) One listed for liver transplant Mean duration for recovery 37 ± 16 days IDDF2022-ABS-0185 Figure 1ConclusionsGiloy, a commonly used immunity booster, can produce drug-induced liver injury, which often mimics autoimmune hepatitis and responds to steroids.

表1吉洛伊致肝损伤患者的临床特征特征患者人数(共16例)性别男7(43.75%)女9(56.25%)年龄(平均±SD) 48.3±14岁表现类型急性肝炎6 (37.5%)ACLF 10(62.5%)吉洛伊消耗后症状出现的平均持续时间84.3±35天平均BMI 23.23±3 kg/m2合并症2型糖尿病9(56.25%)肺间质性疾病(吸入性类固醇)2(12.5%)高血压1 (6.25%)没有5(31.25%)非酒精性脂肪肝2例(6.25%)症状16(100%)腹水黄疸8(50%)疲劳12(75%)瘙痒4(25%)肝功能测试峰值总胆红素(平均数±标准差)17±9.4 mg / dl峰值ALT(平均数±标准差)365±219 U / L峰值AST(平均数±标准差)558±475 U / L峰值高山(平均数±标准差)186±114 U / L峰值血清免疫球蛋白(平均±SD) 2400±1213 mg / dl INR峰值(平均数±标准差)2.63±1.05 AIH血清学安娜1 (6.25%)ASMA -反LKM1 AMA -血清反应阴性的(活检证实)- 10(62.5)肝脏活组织检查药物诱导肝损伤5(31.25%) AIH 5特点(31.25%)治疗方法n -乙酰半胱氨酸输注+腺苷- 3(18.75%)类固醇10(62.5%)血浆置换3(18.75%)预后存活16(100%)1例肝移植患者平均恢复时间37±16天IDDF2022-ABS-0185图1结论giloy是常用的免疫增强剂，可引起药物性肝损伤，通常与自身免疫性肝炎相似，对类固醇有应答。

{"title":"IDDF2022-ABS-0185 Tinospora cordifolia induced liver injury during covid-19 pandemic","authors":"Sowmya Iyengar, A. Kulkarni, Mithun Sharma, D. Nageshwar Reddy, P. Rao","doi":"10.1136/gutjnl-2022-iddf.115","DOIUrl":"https://doi.org/10.1136/gutjnl-2022-iddf.115","url":null,"abstract":"IDDF2022-ABS-0185 Table 1Clinical characteristics of patients with Giloy-induced liver injuryCharacteristics Number of patients (Total-16 patients) Gender Male 7 (43.75%) Female 9 (56.25%) Age (mean ± SD) 48.3±14 years Presentation type Acute hepatitis 6 (37.5%) ACLF 10 (62.5%) Mean duration for symptom onset after consumption of giloy 84.3±35 days Mean BMI 23.23±3 kg/m2 Comorbidities Type 2 diabetes 9 (56.25%) Interstitial lung disease (on inhalational steroids) 2 (12.5%) Hypertension 1 (6.25%) None 5 (31.25%) NAFLD 2 (6.25%) Symptoms Jaundice 16 (100%) Ascites 8 (50%) Fatigue 12 (75%) Pruritus 4 (25%) Liver function tests Peak total bilirubin (Mean ± SD) 17 ± 9.4 mg/dl Peak ALT (mean ± SD) 365± 219 U/L Peak AST (mean ± SD) 558 ± 475 U/L Peak ALP (mean ± SD) 186 ± 114 U/L Peak serum IgG (mean ± SD) 2400 ± 1213 mg/dl Peak INR (mean ± SD) 2.63 ± 1.05 AIH serology ANA 1(6.25%) ASMA - Anti LKM1 - AMA - Seronegative (biopsy proven) - Liver biopsy 10 (62.5) Drug induced liver injury 5 (31.25%) Features of AIH 5 (31.25%) Treatment N-Acetyl Cysteine infusion+Ademetionine 3 (18.75%) Steroids 10 (62.5%) Plasma Exchange 3 (18.75%) Outcome Alive 16 (100%) One listed for liver transplant Mean duration for recovery 37 ± 16 days IDDF2022-ABS-0185 Figure 1ConclusionsGiloy, a commonly used immunity booster, can produce drug-induced liver injury, which often mimics autoimmune hepatitis and responds to steroids.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88943750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IDDF2022-ABS-0281 Umbilico-bilious fistula-a diagnostic challenge 脐胆管瘘-诊断挑战

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.134

Parveen Kumar, V. Manchanda, M. Sengar

引用次数: 0

IDDF2022-ABS-0016 Clinical profile and outcome of liver abscess in children: a single centre experience from North India 儿童肝脓肿的临床特征和结局:来自北印度的单中心经验

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.85

I. Chaudhuri, M. Narang, D. Shah, S. Gupta, L. Upreti

引用次数: 0

IDDF2022-ABS-0182 Comparing the diagnostic accuracy of renal resistive index and urine neutrophil gelatinase-associated lipocalin (NGAL) in differentiating type of acute kidney injury in decompensated cirrhosis 肾抵抗指数与尿中性粒细胞明胶酶相关脂钙蛋白(NGAL)鉴别失代偿期肝硬化急性肾损伤类型的诊断准确性比较

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.114

Roshan George, Ajay Kumar, U. Sonika

引用次数: 0

IDDF2022-ABS-0117 A retrospective study into etiology, clinical outcomes and prognostic factors of severe acute liver injury in hong kong 香港严重急性肝损伤的病因、临床结局和预后因素回顾性研究

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.98

Ka-Yan Gloria Chan

引用次数: 1

IDDF2022-ABS-0243 Incidence of liver cancer by histological subtypes in 2020: a global study 2020年肝癌组织学亚型发病率:一项全球研究

Chinese Journal of Clinical Hepatology

Pub Date : 2022-09-01 DOI: 10.1136/gutjnl-2022-iddf.126

Junjie Huang, Veeleah Lok, Lin Zhang, D. Lucero‐Prisno, Wanghong Xu, Z. Zheng, Edmar Elcarte, M. Withers, Martin C. S. Wong

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Chinese Journal of Clinical Hepatology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀